We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL.
- Authors
Garand, R; Beldjord, K; Cavé, H; Fossat, C; Arnoux, I; Asnafi, V; Bertrand, Y; Boulland, M-L; Brouzes, C; Clappier, E; Delabesse, E; Fest, T; Garnache-Ottou, F; Huguet, F; Jacob, M-C; Kuhlein, E; Marty-Grès, S; Plesa, A; Robillard, N; Roussel, M
- Abstract
Minimal residual disease (MRD) quantification is widely used for therapeutic stratification in pediatric acute lymphoblastic leukemia (ALL). A robust, reproducible, sensitivity of at least 0.01% has been achieved for IG/TCR clonal rearrangements using allele-specific quantitative PCR (IG/TCR-QPCR) within the EuroMRD consortium. Whether multiparameter flow cytometry (MFC) can reach such inter-center performance in ALL MRD monitoring remains unclear. In a multicenter study, MRD was measured prospectively on 598 follow-up bone marrow samples from 102 high-risk children and 136 adult ALL patients, using IG/TCR-QPCR and 4/5 color MFC. At diagnosis, all 238 patients (100%) had at least one suitable MRD marker with 0.01% sensitivity, including 205/238 samples (86%) by using IG/TCR-QPCR and 223/238 samples (94%) by using MFC. QPCR and MFC were evaluable in 495/598 (83%) samples. Qualitative results (<0.01% or 0.01%) concurred in 96% of samples and overall positivity (including <0.01% and nonquantifiable positivity) was concurrent in 84%. MRD values 0.01% correlated highly (r2=0.87) and 69% clustered within half-a-log10. QPCR and MFC can therefore be comparable if properly standardized, and are highly complementary. MFC strategies will benefit from a concerted approach, as does molecular MRD monitoring, and will contribute significantly to the achievement of 100% MRD informativity in adult and pediatric ALL.
- Subjects
FLOW cytometry; LYMPHOBLASTIC leukemia treatment; ALLELES; BONE marrow; CANCER patients; CLONE cells
- Publication
Leukemia (08876924), 2013, Vol 27, Issue 2, p370
- ISSN
0887-6924
- Publication type
Article
- DOI
10.1038/leu.2012.234